No immediate effect on urodynamic parameters during transcutaneous electrical nerve stimulation (TENS) in children with overactive bladder and daytime incontinence-A randomized, double-blind, placebo-controlled study

2016 ◽  
Vol 36 (7) ◽  
pp. 1788-1795 ◽  
Author(s):  
Luise Borch ◽  
Soeren Rittig ◽  
Konstantinos Kamperis ◽  
Birgitte Mahler ◽  
Jens Christian Djurhuus ◽  
...  
Keyword(s):  
Overactive Bladder ◽  
Nerve Stimulation ◽  
Transcutaneous Electrical Nerve Stimulation ◽  
Controlled Study ◽  
Double Blind ◽  
Electrical Nerve Stimulation ◽  
Double Blind Placebo ◽  
Urodynamic Parameters

scholarly journals Transcutaneous electrical nerve stimulation and solifenacin succinate versus solifenacin succinate alone for treatment of overactive bladder syndrome: A double-blind randomized controlled study

PLoS ONE ◽  
2021 ◽  
Vol 16 (6) ◽  
pp. e0253040
Author(s):  
Yumeng Zhang ◽  
Shaoyong Wang ◽  
Shulu Zu ◽  
Chanjuan Zhang
Keyword(s):  
Overactive Bladder ◽  
Nerve Stimulation ◽  
Transcutaneous Electrical Nerve Stimulation ◽  
Controlled Study ◽  
Double Blind ◽  
Electrical Nerve Stimulation ◽  
Randomized Controlled ◽  
Solifenacin Succinate ◽  
Group A ◽  
Group B

Objective We evaluated a combination of transcutaneous electrical nerve stimulation (TENS) and solifenacin succinate versus solifenacin alone in the treatment of overactive bladder (OAB). Methods Ninety-seven female outpatients with OAB were screened for this double-blind randomized controlled study. Eighty-six patients who met our inclusion criteria were divided randomly into two groups. In group A (43 patients), patients received oral solifenacin and “fake” TENS on the foot; in group B (43 patients), patients received oral solifenacin and effective TENS on the foot. Improvements in OAB symptoms were assessed by Overactive Bladder Symptom Score (OABSS), Overactive Bladder Questionnaire (OAB-q), voiding diaries and urodynamic tests. 70 of 86 patients (36 in group A, 34 in group B) completed the 2 months of treatment and 3 months of follow-up. Results Statistically, the maximum bladder volume and OAB symptoms of both groups improved significantly after treatment. The improvement in group B was significantly better than that in group A, as indicated by the maximum bladder volume, OAB-q score and voiding diary. Some mild adverse effects were observed, including dry mouth, stomach upset, constipation, muscle pain and local paresthesia. Conclusion The combination of TENS and solifenacin was more effective in improving OAB symptoms than solifenacin alone.

scholarly journals Effect of Transcutaneous Electrical Nerve Stimulation on Pain, Function, and Quality of Life in Fibromyalgia: A Double-Blind Randomized Clinical Trial

2015 ◽  
Vol 95 (1) ◽  
pp. 129-140 ◽  
Author(s):  
Brian Noehren ◽  
Dana L. Dailey ◽  
Barbara A. Rakel ◽  
Carol G.T. Vance ◽  
Miriam B. Zimmerman ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Clinical Trial ◽  
Nerve Stimulation ◽  
Transcutaneous Electrical Nerve Stimulation ◽  
Treatment Modalities ◽  
Double Blind ◽  
Electrical Nerve Stimulation ◽  
Double Blind Placebo ◽  
Patient Reported

BackgroundFibromyalgia is a common chronic pain condition that has a significant impact on quality of life and often leads to disability. To date, there have been few well-controlled trials assessing the utility of nonpharmacological treatment modalities such as transcutaneous electrical nerve stimulation (TENS) in the management of pain and improvement in function in individuals with fibromyalgia.ObjectivesThe purpose of this study will be to complete a long-term, multicenter study to assess the effects of TENS in women with fibromyalgia.DesignThis will be a phase II randomized, double-blind, placebo-controlled, multicenter clinical trial.ParticipantsThree hundred forty-three participants with fibromyalgia will be recruited for this study.InterventionParticipants will be randomly assigned to 1 of 3 groups: the intervention (TENS), placebo, or no treatment. After completing the randomized period, all participants will receive the intervention for 1 month. The participants will be asked to use TENS at the highest tolerable level for at least 2 hours daily during physical activity.MeasurementsThe primary outcome will be pain with movement, with secondary outcomes assessing functional abilities, patient-reported outcomes, and quantitative sensory testing.LimitationsBecause having participants refrain from their typical medications is not practical, their usage and any change in medication use will be recorded.ConclusionsThe results of this study will provide some of the first evidence from a large-scale, double-blind, placebo-controlled trial on the effectiveness of TENS on pain control and quality-of-life changes in patients with fibromyalgia.

Sign in / Sign up

Export Citation Format

Share Document